{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:39:52Z","timestamp":1791614392422,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["NWA.1389.20.244"],"award-info":[{"award-number":["NWA.1389.20.244"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum. Genet."],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Currently, new research projects aim to develop prognostic models that more accurately predict the age of onset and progression of disease for adult-onset autosomal dominant neurodegenerative diseases that lack disease-modifying treatments. While such predictions can be important for medical research and valuable in clinical practice, the perspectives of mutation carriers on receiving onset and progression predictions have not yet been explored. In this Dutch qualitative interview study, conducted between May and August 2023, the preferences, views, and concerns of 25 asymptomatic mutation carriers of Huntington\u2019s Disease, Spinocerebellar Ataxia type 1, or Spinocerebellar Ataxia type 3 regarding onset and progression predictions were examined. Reasons for wanting to receive onset and progression predictions included life planning, preparing for the disease, informing family members, and reducing uncertainty and hypervigilance. Reasons against included concerns about negative psychological effects, the expectation of similar disease progression as family members, and a preference for receiving progression information at a later stage. Most participants were open towards disclosure of onset predictions but more hesitant regarding receiving progression information. The reasons expressed and the preferred predicted age ranges varied among age groups, and some differences in preferences were observed between the three diseases. These findings may guide the development and responsible implementation of such prognostic models and can support healthcare professionals in the counselling of mutation carriers of adult-onset genetic neurodegenerative diseases.<\/jats:p>","DOI":"10.1007\/s00439-025-02750-0","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T05:16:51Z","timestamp":1748236611000},"page":"665-677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring mutation carriers\u2019 preferences regarding onset and progression of disease predictions for adult-onset genetic neurodegenerative diseases: a qualitative interview study"],"prefix":"10.1007","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4799-8587","authenticated-orcid":false,"given":"Max J.","family":"Rensink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. H. N.","family":"Schermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tibben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. K.","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. T.","family":"de Bot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Kievit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. L. E.","family":"Bolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"2750_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s11606-008-0803-x","volume":"23","author":"AJ Apter","year":"2008","unstructured":"Apter AJ, Paasche-Orlow MK, Remillard JT, Bennett IM, Ben-Joseph EP, Batista RM, Hyde J, Rudd RE (2008) Numeracy and communication with patients: they are counting on Us. J Gen Intern Med 23:2117\u20132124","journal-title":"J Gen Intern Med"},{"key":"2750_CR2","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/ejhg.2016.36","volume":"24","author":"SS Baig","year":"2016","unstructured":"Baig SS, Strong M, Rosser E, Taverner NV, Glew R, Miedzybrodzka Z, Clarke A, Craufurd D, Quarrell OW (2016) 22 Years of predictive testing for Huntington\u2019s disease: the experience of the UK Huntington\u2019s prediction consortium. Eur J Hum Genet 24:1396\u20131402","journal-title":"Eur J Hum Genet"},{"key":"2750_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/mds.870130120","volume":"13","author":"GD Boo","year":"1998","unstructured":"Boo GD, Tibben A, Hermans J, Maat A, Roos RAC (1998) Subtle involuntary movements are not reliable indicators of incipient Huntington\u2019s disease. Mov Disorders: Official J Mov Disorder Soc 13:96\u201399","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"key":"2750_CR4","unstructured":"Caron NS, Wright GEB, Hayden MR (2020) Huntington disease. GeneReviews\u00ae[Internet]"},{"key":"2750_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1023\/A:1022971113683","volume":"26","author":"SM Cox","year":"2003","unstructured":"Cox SM (2003) Stories in decisions: how at-risk individuals decide to request predictive testing for huntington disease. Qualitative Sociol 26:257\u2013280","journal-title":"Qualitative Sociol"},{"key":"2750_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0140-6736(89)90722-8","volume":"2","author":"D Craufurd","year":"1989","unstructured":"Craufurd D, Dodge A, Kerzin-Storrar L, Harris R (1989) Uptake of presymptomatic predictive testing for Huntington\u2019s disease. Lancet 2:603\u2013605","journal-title":"Lancet"},{"key":"2750_CR7","unstructured":"CureQ (2022) CureQ website. Accessed 07-02-2025. https:\/\/cureq.nl\/cureq-en\/"},{"key":"2750_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/B978-0-444-63233-3.00017-8","volume":"147","author":"R Ghosh","year":"2018","unstructured":"Ghosh R, Tabrizi SJ (2018) Huntington disease. Handb Clin Neurol 147:255\u2013278","journal-title":"Handb Clin Neurol"},{"key":"2750_CR9","unstructured":"Government of the Netherlands Is euthanasia allowed? Ministry of Health, Welfare and Sport. https:\/\/www.government.nl\/topics\/euthanasia\/is-euthanasia-allowed. Accessed 10-30-2024"},{"key":"2750_CR10","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S1474-4422(15)00202-1","volume":"14","author":"H Jacobi","year":"2015","unstructured":"Jacobi H, du Montcel ST, Bauer P, Giunti P, Cook A, Labrum R, Parkinson MH, Durr A, Brice A, Charles P (2015) Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol 14:1101\u20131108","journal-title":"Lancet Neurol"},{"key":"2750_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1399-0004.2007.00910.x","volume":"72","author":"C Kieling","year":"2007","unstructured":"Kieling C, Prestes PR, Saraiva-Pereira ML, Jardim LB (2007) Survival estimates for patients with Machado-Joseph disease (SCA3). Clin Genet 72:543\u2013545","journal-title":"Clin Genet"},{"key":"2750_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/15265160902874320","volume":"9","author":"AA Kon","year":"2009","unstructured":"Kon AA (2009) The role of empirical research in bioethics. Am J Bioeth 9:59\u201365. https:\/\/doi.org\/10.1080\/15265160902874320","journal-title":"Am J Bioeth"},{"key":"2750_CR13","doi-asserted-by":"publisher","first-page":"18928","DOI":"10.1038\/s41598-022-18848-8","volume":"12","author":"I Koval","year":"2022","unstructured":"Koval I, Dighiero-Brecht T, Tobin AJ, Tabrizi SJ, Scahill RI, Tezenas du Montcel S, Durrleman S, Durr A (2022) Forecasting individual progression trajectories in huntington disease enables more powered clinical trials. Sci Rep 12:18928","journal-title":"Sci Rep"},{"key":"2750_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0896-6273(03)00328-3","volume":"38","author":"AR La Spada","year":"2003","unstructured":"La Spada AR, Taylor JP (2003) Polyglutamines placed into context. Neuron 38:681\u2013684","journal-title":"Neuron"},{"key":"2750_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153B","author":"DR Langbehn","year":"2010","unstructured":"Langbehn DR, Hayden MR, Paulsen JS, the P-HDIotHSG (2010) CAG-repeat length and the age of onset in huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 153B:397\u2013408","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"2750_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1179\/hrge.11.2.e35336gt18776032","volume":"11","author":"A Lilani","year":"2005","unstructured":"Lilani A (2005) Ethical issues and policy analysis for genetic testing: Huntington\u2019s disease as a paradigm for diseases with a late onset. Hum Reprod Genetic Ethics 11:28\u201334","journal-title":"Hum Reprod Genetic Ethics"},{"key":"2750_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/mgg3.238","volume":"5","author":"P Mandich","year":"2017","unstructured":"Mandich P, Lamp M, Gotta F, Gulli R, Iacometti A, Marchese R, Bellone E, Abbruzzese G, Ferrandes G (2017) 1993\u20132014: two decades of predictive testing for Huntington\u2019s disease at the medical genetics unit of the university of Genoa. Mol Genet Genom Med 5:473\u2013480","journal-title":"Mol Genet Genom Med"},{"key":"2750_CR18","doi-asserted-by":"crossref","unstructured":"Mank A, van Maurik IS, Bakker ED, van de Glind EMM, J\u00f6nsson L, Kramberger MG, Novak P, Diaz A, Gove D, Scheltens P (2021) Identifying relevant outcomes in the progression of Alzheimer\u2019s disease; what do patients and care partners want to know about prognosis? Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions 7: e12189","DOI":"10.1002\/trc2.12189"},{"key":"2750_CR19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/mdc3.13148","volume":"8","author":"M Oosterloo","year":"2021","unstructured":"Oosterloo M, de Greef BTA, Bijlsma EK, Durr A, Tabrizi SJ, Estevez-Fraga C, de Die\u2010Smulders CEM, Roos RAC (2021) Disease onset in Huntington\u2019s disease: when is the conversion? Mov Disorders Clin Pract 8:352\u2013360","journal-title":"Mov Disorders Clin Pract"},{"key":"2750_CR20","unstructured":"Opal P, Ashizawa T (2017) Spinocerebellar ataxia type 1. GeneReviews\u00ae[Internet]"},{"key":"2750_CR21","unstructured":"Paulson H, Shakkottai V (2020) Spinocerebellar ataxia type 3. GeneReviews\u00ae[Internet]"},{"key":"2750_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"MD Rawlins","year":"2016","unstructured":"Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJW, Smeeth L (2016) The prevalence of Huntington\u2019s disease. Neuroepidemiology 46:144\u2013153","journal-title":"Neuroepidemiology"},{"key":"2750_CR23","doi-asserted-by":"crossref","unstructured":"Sampaio C (2024) Huntington disease\u2013Update on ongoing therapeutic developments and a look toward the future. Parkinsonism & Related Disorders: 106049","DOI":"10.1016\/j.parkreldis.2024.106049"},{"key":"2750_CR24","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1212\/01.wnl.0000325057.33666.72","volume":"71","author":"T Schmitz-Hubsch","year":"2008","unstructured":"Schmitz-Hubsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, Filla A, Mariotti C, Rakowicz M, Charles P (2008) Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology 71:982\u2013989","journal-title":"Neurology"},{"key":"2750_CR25","doi-asserted-by":"publisher","first-page":"117082","DOI":"10.1016\/j.jns.2020.117082","volume":"417","author":"SSO Scott","year":"2020","unstructured":"Scott SSO, Pedroso JL, Barsottini OGP, Fran\u00e7a-Junior MC, Braga-Neto P (2020) Natural history and epidemiology of the spinocerebellar ataxias: insights from the first description to nowadays. J Neurol Sci 417:117082. https:\/\/doi.org\/10.1016\/j.jns.2020.117082","journal-title":"J Neurol Sci"},{"key":"2750_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3233\/JHD-140109","volume":"3","author":"EJ Sitek","year":"2014","unstructured":"Sitek EJ, Thompson JC, Craufurd D, Snowden JS (2014) Unawareness of deficits in Huntington\u2019s disease. J Huntington\u2019s Disease 3:125\u2013135","journal-title":"J Huntington\u2019s Disease"},{"key":"2750_CR27","doi-asserted-by":"crossref","unstructured":"Tabrizi SS, Gantman EC, Mansbach A, Borowsky B, Konstantinova P, Mestre TA, Panagoulias J, Ross CA, Zauderer M, Mullin AP, Romero K, Sivakumaran S, Turner EC, Long JD, Sampaio C (2022) Huntington\u2019s Disease Regulatory Science C A biological classification of Huntington\u2019s disease: the Integrated Staging System. Lancet Neurol 21:632\u2013644","DOI":"10.1016\/S1474-4422(22)00120-X"},{"key":"2750_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.brainresbull.2006.10.023","volume":"72","author":"A Tibben","year":"2007","unstructured":"Tibben A (2007) Predictive testing for Huntington\u2019s disease. Brain Res Bull 72:165\u2013171","journal-title":"Brain Res Bull"},{"key":"2750_CR29","doi-asserted-by":"crossref","unstructured":"Tibben A, Niermeijer MF, Roos RAC, Van De Vlis MV, Frets PG, van Ommen GJB, van de Kamp JJP, Verhage F (1992) Understanding the low uptake of presymptomatic DNA testing for Huntington\u2019s disease. Lancet 340:8832.","DOI":"10.1016\/0140-6736(92)92610-R"},{"key":"2750_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 19:349\u2013357. https:\/\/doi.org\/10.1093\/intqhc\/mzm042","journal-title":"Int J Qual Health Care"},{"key":"2750_CR31","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/brainsci11121597","volume":"11","author":"RM van Eenennaam","year":"2021","unstructured":"van Eenennaam RM, Koppenol LS, Kruithof WJ, Kruitwagen-van Reenen ET, Pieters S, van Es MA, van den Berg LH, Visser-Meily JMA, Beelen A (2021) Discussing personalized prognosis empowers patients with amyotrophic lateral sclerosis to regain control over their future: a qualitative study. Brain Sci 11:1597","journal-title":"Brain Sci"},{"key":"2750_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12910-018-0246-9","volume":"19","author":"T Wangmo","year":"2018","unstructured":"Wangmo T, Hauri S, Gennet E, Anane-Sarpong E, Provoost V, Elger BS (2018) An update on the empirical turn in bioethics: analysis of empirical research in nine bioethics journals. BMC Med Ethics 19:6. https:\/\/doi.org\/10.1186\/s12910-018-0246-9","journal-title":"BMC Med Ethics"},{"key":"2750_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1474-4422(18)30089-9","volume":"17","author":"H-J Westeneng","year":"2018","unstructured":"Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S (2018) Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 17:423\u2013433","journal-title":"Lancet Neurol"},{"key":"2750_CR34","doi-asserted-by":"publisher","first-page":"11662","DOI":"10.1038\/s41598-020-68301-x","volume":"10","author":"JH Won","year":"2020","unstructured":"Won JH, Kim M, Youn J, Park H (2020) Prediction of age at onset in Parkinson\u2019s disease using objective specific neuroimaging genetics based on a sparse canonical correlation analysis. Sci Rep 10:11662. https:\/\/doi.org\/10.1038\/s41598-020-68301-x[pii]","journal-title":"Sci Rep"}],"container-title":["Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00439-025-02750-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00439-025-02750-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00439-025-02750-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T12:05:59Z","timestamp":1750075559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00439-025-02750-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2750"],"URL":"https:\/\/doi.org\/10.1007\/s00439-025-02750-0","relation":{},"ISSN":["0340-6717","1432-1203"],"issn-type":[{"value":"0340-6717","type":"print"},{"value":"1432-1203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Susanne T. de Bot: Leiden University Medical Centre received grants from the European Huntington\u2019s Disease Network (EHDN) and Cure HD Initiative (CHDI), participates in an EU Horizon 2020 project: Innovative Medicines Initiative (IMI) 2 (IDEA_FAST), and participates in clinical trials sponsored by PRILENIA, PTC Therapeutics, WAVE and VICO Therapeutics. Susanne T. de Bot is member of the HD Expert Advisory Panel for the PTC518 phase 3 program (PTC Therapeutics). The aforementioned sponsors had no role in the design, execution, interpretation, or writing of this current study. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}